Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus

Journal of Clinical Oncology

Volumn 16, Issue 5, 1998, Pages 1826-1834

  Ilson, David H ^a   Ajani, Jaffer ^a   Bhalla, Kapil ^a   Forastiere, Arlene ^a   Huang, Ying ^a   Patel, Paresh ^a   Martin, Lisa ^a   Donegan, Janet ^a   Pazdur, Richard ^a   Reed, Carolyn ^a   Kelsen, David P ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FLUOROURACIL; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG RESPONSE; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0031831196     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.5.1826     Document Type: Article

References (35)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1996. CA Cancer J Clin 46:5-27, 1996
2. Blot WJ, Devesa SS, Kneller RW, et al: Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287-1289, 1991
3. Ajani JA: Contributions of chemotherapy in the treatment of carcinoma of the esophagus: Results and commentary. Semin Oncol 21:474-482, 1994
4. Ilson DH, Kelsen DP: Systemic therapy in esophageal cancer, in Aisner J, Arriagada R, Green MR, Martini N, Perry MC (eds): Comprehensive Textbook of Thoracic Oncology. Baltimore, MD, Williams & Wilkins, 1996, pp 630-649
5. Ilson DH, Kelsen DP: Combined modality therapy in the treatment of esophageal cancer. Semin Oncol 21:493-507, 1994
6. Wani MC, Taylor HL, Wall ME, et al: Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327, 1971
7. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
8. Ajani J, Ilson D, Daugherty K, et al: Activity of Taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 86:1086-1091, 1994
9. Rowinsky EK, Citardi MJ, Noe DA, et al: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents Taxol and vincristine. J Cancer Res Clin Oncol 119:727-733, 1993
10. Patel GF, Ren QF, Grem J: Interaction of fluorouracil and paclitaxel in MCF-7 human breast carcinoma cells. Proc Am Assoc Cancer Res 35:330, 1994 (abstr)
11. Rowinsky E, Chaudhry V, Forastiere A, et al: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
12. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
13. Klastersky J, Sculier JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small-cell lung cancer. Semin Oncol 21:39-43, 1994
14. Eisenhauer EA, Huinink Bokkel WW, Swenerton KD, et al: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
15. O'Reilly SE, Gelmon KA: Biweekly paclitaxel and cisplatin: A phase I/II study in the first-line treatment of metastatic breast cancer. Semin Oncol 22:109-111, 1995
16. Bhalla KN, Kumar GN, Walle T, et al: Phase I and pharmacokinetic trial of a 3-hour infusion of Taxol, cisplatin plus 5-fluorouracil in advanced solid tumors. Proc Am Soc Clin Oncol 13:165, 1994(abstr)
17. Miller AB, Hoogstraten B, Staquet M, et al: Reporting of cancer treatment. Cancer 47:207-214, 1981
18. Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
19. Kaplan EL, Meier P: Nonparametric estimation for incomplete observation. J Amer Stat Assoc 53:457-481, 1958
20. Ajani JA, Fairweather J, Dumas P, et al: A phase II study of Taxol in patients with advanced untreated gastric carcinoma. Proc Am Soc Clin Oncol 16:263A, 1997 (abstr)
21. Einzig AI, Wiernik PH, Lipsitz S, et al: Phase II trial of Taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT); Proc Am Soc Clin Oncol 12:194, 1993 (abstr)
22. Wasserheit C, Frazein A, Oratz R, et al: Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: An active regimen with limiting neurotoxicity. J Clin Oncol 14:1993-1999, 1996
23. Gordon AN, Stringer CA, Matthews CM, et al: Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: Rapid development of neurotoxicity is dose-limiting. J Clin Oncol 15:1965-1973, 1997
24. Herskovic A, Martz K, Al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593-1598, 1992
25. Al-Sarraf M, Martz K, Herskovic A, et al: Superiority of chemo-radiotherapy (CT-RT) vs radiotherapy (RT) in patients with esophageal cancer. Final report of an intergroup randomized and confirmed study. Proc Am Soc Clin Oncol 15:206, 1996 (abstr)
26. Kok TC, Janschot JV, Siersema PD: Neoadjuvant chemotherapy in operable esophageal squamous cell cancer: Final report of a randomized controlled trial. Rotterdam Esophageal Tumor Study Group. European Organization for Research and Treatment of Cancer EORTC Gastrointestinal Symposium, Nijmegen, the Netherlands, June 20-21, 1996
27. Walsh TN, Noonan N, Hollywood D, et al: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335:462-467, 1996
28. Urba S, Orringer M, Turrisi A, et al: A randomized trial comparing transhiatal esophagectomy (THE) to preoperative concurrent chemoradiation (CT/XRT) followed by esophagectomy in locoregional esophageal carcinoma (CA). Proc Am Soc of Clin Oncol 14:199, 1995 (abstr)
29. Urba S, Orringer M, Turrisi A, et al: A randomized trial comparing surgery (S) to preoperative concomitant chemoradiation plus surgery in patients (pts) with resectable esophageal cancer (CA): Updated analysis. Proc Am Soc Clin Oncol 16:983, 1997 (abstr)
30. Kelsen DP, Ginsberg R, Qian C, et al: Chemotherapy followed by operation versus operation alone in the treatment of patients with localized esophageal cancer: A preliminary report of intergroup study 113 (RTOG 89-11). Proc Am Soc Clin Oncol 16:982, 1997 (abstr)
31. van der Gaast A, Kok TC, Vos R, et al: A phase I dose-finding study of a biweekly schedule of a fixed dose of cisplatin with increasing doses of paclitaxel in patients with advanced esophageal cancer. Semin Oncol 24:S82-S85, 1997 (suppl 19)
32. Costa F, Ilson D, Forastiere A, et al: Phase II study of paclitaxel and cisplatin in patients with advanced adenocarcinoma (A) and squamous cell (S) carcinoma of the esophagus. Proc Am Soc Clin Oncol 16:262A, 1997 (abstr)
33. Javed T, Reed C, Walle T, et al: A regimen of paclitaxel (P), cisplatin (CP) and 5-fluorouracil (FU) followed by G-CSF is highly active against epidermoid and adenocarcinoma of esophagus. Proc Am Soc Clin Oncol 14:456, 1995 (abstr)
34. Belani CP, Luketich JD, Landreaneau RJ, et al: Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. Semin Oncol 24:S89-S92, 1997 (suppl 19)
35. Hainsworth JD, Meluch AA, Greco FA: Paclitaxel, carboplatin, and long-term continuous 5-fluorouracil infusion in the treatment of upper aerodigestive malignancies: Preliminary results of phase II trial. Semin Oncol 24:S38-S42, 1997 (suppl 19)